drugset / Trial / NCT04081220
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
Phase 2
Active not recruiting
9 enrolled
The University of Texas Health Science Center at San Antonio
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
Timeline
- Start
- 2020-04-09
- Primary completion
- 2023-12-20
- Completion
- 2026-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bomedemstat | Small molecule | — | Oral |